-
Mashup Score: 1Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis - 2 month(s) ago
Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disease characterized by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5 receptor (anti-IL-5R) monoclonal antibody, induces rapid depletion of eosinophils; its longer-term effect in EGPA is unknown.
Source: www.jaci-inpractice.orgCategories: General Medicine News, Allergy-ImmunologyTweet
In Current Issue! #Long-Term Effectiveness of #Benralizumab in #Eosinophilic #Granulomatosis With #Polyangiitis https://t.co/D4b3xk53pG https://t.co/tjahu8IuUM